# Thomas Lars Andresen

> Thomas Lars Andresen is a Danish scientist, engineer and serial company founder. A former software developer at Danmarks Radio, he became a professor and department head at the Technical University of Denmark, co-founded several companies, and served as founding CEO of T-Cypher Bio. He became CEO of Commit Biologics on 16 March 2026 and remains listed as T-Cypher’s founding CEO and non-executive director.

- **Role:** CEO at Commit Biologics; Founding CEO / Non-Executive Director at T-Cypher Bio
- **Organizations:** Commit Biologics, T-Cypher Bio, Technical University of Denmark, Torque Therapeutics, Repertoire Immune Medicines, Nanovi, Monta Biosciences, Precision Antibiotics, Hazel Therapeutics, X-Therapeutics, Tidal Therapeutics, LiPlasome Pharma, Danmarks Radio
- **From:** Copenhagen, Denmark
- **Nationality:** Danish
- **Education:** MSc in Engineering, Technical University of Denmark and University of Auckland, PhD, Technical University of Denmark
- **Known for:** Recipient of the 2017 EliteForsk Prize, worth DKK 1.2 million: DKK 200,000 personal award and DKK 1 million for research., Recipient of an ERC Starting Grant and a 2015 Sapere Aude DFF-Advanced Grant., Co-author of more than 220 research articles, according to current company biographies.

## Career timeline

- **1994-1996** — Software developer at Danmarks Radio.
- **2001** — Completed MSc in Engineering, associated with DTU and University of Auckland in his published CV.
- **2001-2007** — Research leadership at LiPlasome Pharma.
- **2005** — Completed PhD, attributed to DTU in his 2017 and 2019 CVs.
- **2007** — Joined Risø National Laboratory; DTU CV lists associate professorship in chemistry and biomaterials.
- **2012** — Appointed full professor at DTU.
- **2013** — Co-founded Nanovi.
- **2014** — Deputy director and acting department head at DTU Nanotech.
- **2015** — Co-founded Torque Therapeutics and Monta Biosciences; received Sapere Aude grant.
- **2016** — Appointed head of DTU Nanotech, effective 1 December.
- **2017** — Received EliteForsk Prize on 23 February.
- **2018** — Lived and worked in Boston as Torque Therapeutics chief scientific officer from April.
- **2019** — Appointed director of newly created DTU department effective 1 April; DTU’s updated notice records departure effective 26 April.
- **2021** — Appointed CEO and board member of T-Cypher Bio, effective 1 August.
- **2026** — Became CEO of Commit Biologics, effective 16 March.

## Achievements

- Recipient of the 2017 EliteForsk Prize, worth DKK 1.2 million: DKK 200,000 personal award and DKK 1 million for research.
- Recipient of an ERC Starting Grant and a 2015 Sapere Aude DFF-Advanced Grant.
- Co-author of more than 220 research articles, according to current company biographies.
- Named on more than 50 patent applications, according to T-Cypher’s current biography.
- Co-founded companies including Nanovi, Torque Therapeutics and Monta Biosciences.

## Latest updates

- **2026-03** — Commit Biologics announced his appointment on 11 March, effective 16 March.
- **2026-03** — In a public LinkedIn post, described returning to the Danish business ecosystem after years working in the US and UK.

## Links

- LinkedIn: https://www.linkedin.com/in/thomas-montgomery-andresen/

---

Profile page: https://yespress.io/thomas-lars-andresen
Published by YesPress — https://yespress.io
Last updated: 2026-10-11